Pharmacology and antifungal properties of anidulafungin, a new echinocandin

Pharmacotherapy
Kristina E EstesThomas J Walsh

Abstract

Anidulafungin is the third echinocandin antifungal agent to receive approval from the United States Food and Drug Administration. It is indicated for the treatment of esophageal candidiasis, candidemia, and other candidal infections. Anidulafungin is fungicidal against Candida species, including Candida glabrata and isolates resistant to azoles and polyenes. The drug's efficacy is comparable to that of fluconazole for the treatment of esophageal candidiasis, and it is effective in patients with invasive candidiasis and candidemia. Anidulafungin is distinct among the echinocandins in that it undergoes slow, nonenzymatic chemical degradation. As a consequence, impairments in renal or hepatic function do not substantially alter its pharmacokinetics. In addition, anidulafungin has not demonstrated any drug-drug interactions because it is not a substrate, inhibitor, or inducer of the cytochrome P450 enzyme system. Anidulafungin is well tolerated in adults and pediatric patients, with few reported adverse drug events. The safety, tolerability, and potent fungicidal activity of anidulafungin against Candida species make it a reasonable alternative in the treatment of patients with serious candidal infections.

References

Sep 3, 1999·Antimicrobial Agents and Chemotherapy·R PetraitieneT J Walsh
Dec 10, 1999·Journal of the American College of Cardiology·K S WooD S Celermajer
Feb 19, 2002·Antimicrobial Agents and Chemotherapy·Julie A StoneScott A Waldman
Oct 11, 2003·Lancet·David W Denning
May 18, 2004·Journal of Clinical Pharmacology·James A DowellTim Henkel
May 25, 2004·Antimicrobial Agents and Chemotherapy·David S KrauseUNKNOWN Anidulafungin Invasive Candidiasis Study Group
Aug 13, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Hilmar WisplinghoffMichael B Edmond
Oct 9, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David S KrauseTimothy Henkel
Oct 9, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kieren A MarrLawrence Corey
Jul 29, 2005·Antimicrobial Agents and Chemotherapy·Nita L SeibelThomas J Walsh
Nov 2, 2005·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·L Ostrosky-ZeichnerD N Buell
Nov 18, 2005·Journal of Clinical Pharmacology·James A DowellGrover Foster
Jan 18, 2006·International Journal of Antimicrobial Agents·James A KarlowskyBeth P Goldstein
Feb 9, 2006·The Journal of Antimicrobial Chemotherapy·Michel LaverdièreDavid S Perlin
Feb 27, 2007·Journal of Clinical Pharmacology·James A DowellBharat Damle
Apr 11, 2007·Antimicrobial Agents and Chemotherapy·Padmaja PaderuDavid S Perlin
Jun 15, 2007·The New England Journal of Medicine·Annette C ReboliUNKNOWN Anidulafungin Study Group

❮ Previous
Next ❯

Citations

Nov 26, 2009·Drugs·Antonino Gullo
Nov 26, 2009·Drugs·Teresita Mazzei, Andrea Novelli
Aug 7, 2009·Expert Opinion on Investigational Drugs·Susanne Perkhofer, Cornelia Lass-Flörl
Sep 9, 2010·Expert Opinion on Drug Metabolism & Toxicology·Effie L Kuti, Joseph L Kuti
Feb 1, 2011·Early Human Development·Kevin WattMichael Cohen-Wolkowiez
Apr 20, 2010·International Journal of Antimicrobial Agents·Suganthini Krishnan-NatesanPranatharthi H Chandrasekar
Oct 25, 2011·Journal of Clinical Pharmacy and Therapeutics·C B Hindahl, J W Wilson
Dec 17, 2009·Mycoses·Paul O Gubbins, Seth Heldenbrand
Nov 15, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Daniel Aguilar-ZapataVidmantas Petraitis
May 4, 2013·Clinical Medicine Insights. Pediatrics·Michael H Wilke
May 5, 2020·Journal of Biomedical Materials Research. Part a·Noel Vera-GonzálezAnita Shukla
Jan 6, 2018·The Journal of Antimicrobial Chemotherapy·Emily L LarkinMahmoud A Ghannoum
Dec 4, 2019·Current Opinion in Anaesthesiology·Pedro PóvoaIgnacio Martin-Loeches
May 8, 2018·Indian Journal of Medical Microbiology·Subramanian SwaminathanNalini Adele Pinto

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Related Papers

Antimicrobial Agents and Chemotherapy
Bharat DamleJames Dowell
The New England Journal of Medicine
Annette C ReboliAnidulafungin Study Group
The New England Journal of Medicine
Scott K Aberegg, James M O'Brien
© 2021 Meta ULC. All rights reserved